Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
988 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.75 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 32.58 | Oscillator | Neutral |
| Williams %R (14) | -77.27 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.06 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 20.54 (+DI 15.9 / -DI 25.9) | Trend |
Current price $1.73
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jan 9, 26 |
| EMA 20 | 1.83 | MA | Strong Sell |
| SMA 20 | 1.86 | MA | Strong Sell |
| EMA 50 | 1.88 | MA | Strong Sell |
| SMA 50 | 1.98 | MA | Strong Sell |
| SMA 200 | 1.77 | MA | Sell |
| Piper Sandler |
| maintain |
| Overweight |
| Overweight |
| Nov 25, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 14, 25 | Oppenheimer | maintain | Outperform | Outperform |
| May 16, 25 | Jones Trading | downgrade | Buy | Hold |
| May 15, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Mar 28, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Mar 28, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 26, 25 | Citizens Capital Markets | maintain | Market Outperform | Market Outperform |
| Mar 26, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Miller Mary | officer: Chief Legal Officer | S-Sale | 294 @ $1.99 | $585 |
| Aug 31, 26 | Levin Michaela | officer: Chief Business Officer | A-Award | 130,000 @ $2.09 | $271.7K |
| Aug 31, 26 | Levin Michaela | officer: Chief Business Officer | A-Award | 30,000 | — |
| Aug 31, 26 | Levin Michaela | 0 | — | ||
| Aug 25, 26 | Blume-Jensen Peter | director, officer: President and CEO | S-Sale | 14,036 @ $2.21 | $30.97K |
| Aug 18, 26 | Peterson Katharine | officer: Chief Accounting Officer | S-Sale | 101 @ $2.01 | $203 |
| Aug 18, 26 | Miller Mary | officer: Chief Legal Officer | S-Sale | 185 @ $2.01 | $372 |
| Aug 18, 26 | Gamelin Erick | officer: Chief Development Officer | S-Sale | 400 @ $2.01 | $804 |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 7, 2026 | 2026-10-07 17:02:25 | View |
| 4 | Sep 2, 2026 | 2026-09-02 16:30:31 | View |
| 3 | Sep 2, 2026 | 2026-09-02 16:26:32 | View |
| 4 | Aug 27, 2026 | 2026-08-27 16:14:53 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:10:19 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:09:33 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:08:39 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:07:50 | View |
| 4 | Aug 20, 2026 | 2026-08-20 16:07:06 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 11:32:03 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the advancement of ACR-7280, a potential first-in-class, oral CDK11 inhibitor, as its next development candidate generated from its AI-enabled AP3 innovation platform.
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D.
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy
Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimization across AP3-informed solid tumor populations Dose expansion to evaluate biomarker-selected small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), lung adenocarcinoma (adNSCLC), as well as endometrial, cervical, and esophago-gastric junction cancers WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that ACR-2316 has advanced into the randomized dose expansion portion of its ongoing Phase 1/2 study.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.50 | -0.43 | Beat 14.4% | — |
| May 13, 2026 | -0.49 | -0.49 | Beat 0.0% | — |
| Mar 19, 2026 | -0.49 | -0.49 | Beat 0.0% | — |
| Nov 13, 2025 | -0.57 | -0.47 | Beat 17.5% | — |
| Aug 13, 2025 | -0.57 | -0.55 | Beat 3.5% | — |
| May 14, 2025 | -0.57 | -0.51 | Beat 10.5% | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACRV | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.9x | -5.4x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.9x | EPS est. -1.85 | In line |
| Price / Book | 0.8x | -0.9x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.4x | -3.9x | Discount |
| Return on equity | -70.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.02 | -0.02 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -2.54 | Distress |
Discounted cash flow model